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Background: Sodium chloride (NaCl) reabsorption in the cortical thick ascending limb (cTAL) is regulated by opposing effects. Nitric
oxide (NO) inhibits NaCl reabsorption while 8-iso-prostaglandin-F2α (8-iso-PGF2α) stimulates it. Their interaction has not been evaluated in the cTAL. Because 8-iso-PGF2α has considerable stability while NO is a free radical with a short half-life, we hypothesized that,
in the cTAL, the inhibition of NaCl absorption will be reversed by 8-iso-PGF2α.
Methods: Chloride absorption (JCl) was measured in isolated perfused cTALs and whether the activation of protein kinase A (PKA) is
required for this interaction. Since cyclic adenosine monophosphate (cAMP) is a major messenger for the 8-iso-PGF2α signaling cascade, and NO inhibits JCl by decreasing cAMP bioavailability, we measured 8-iso-PGF2α-stimulated cAMP in the presence of sodium
nitroprusside (SNP).
Results: The NO donor, SNP (10-6 M), decreased JCl by 41%, while luminal 8-iso-PGF2α (100 μM) increased JCl to 315 ± 46 pmol/min/
mm (p < 0.003), reversing the effects of the NO donor. SNP inhibited JCl, 8-iso-PGF2α failed to increase JCl in the presence of H89.
Basal cAMP was 56 ± 13 fmol/min/mm, in the presence of SNP 57 ± 6 fmol/min/mm, and 8-iso-PGF2α increased it to 92 ± 2 fmol/
min/mm (p < 0.04).
Conclusion: We concluded that 1) NO-induced inhibition of JCl in the cTAL can be reversed by 8-iso-PGF2α, 2) 8-iso-PGF2α and NO interaction requires PKA to control JCl, and 3) in the presence of NO, 8-iso-PGF2α continues to stimulate JCl because NO cannot reverse
8-iso-PGF2α-stimulated cAMP level.
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Introduction
The nephron segment, cortical thick ascending limb (cTAL)

regulates sodium chloride (NaCl) reabsorption as one of
the most involved segments in NaCl retention states. In
normal conditions, absorption of NaCl is balanced with
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its excretion, maintaining Na balance. This homeostasis is
the final result of the action of molecules increasing and
decreasing transport. However, in pathologic conditions,
such as congestive heart failure, chronic kidney disease,
hypertension, cirrhosis, and other diseases, Na retention
is greater than its excretion, leading to a positive Na imbalance. This Na overload occurs because Na retention
factors overcome the actions of molecules that increase its
excretion, resulting in resistance to natriuretic effects. Understanding the interaction of the autacoids at the different
nephron segments, especially at the cTAL, would help to
elucidate such deleterious conditions and find strategies to
manage them.
Previously, we reported that 8-iso-prostaglandin-F2α
(8-iso-PGF2α) increases Na+ and Cl– reabsorption at the
cTAL [1]. This effect, in vivo, would increase Na balance,
inducing a blood pressure elevation that could be displayed as hypertension, congestive heart failure, cirrhosis,
chronic kidney disease, or other edematous states. On the
other hand, nitric oxide (NO) inhibits Na+ reabsorption at
the cTAL, and this effect, in vivo, would induce diuresis
and natriuresis, a mechanism that would decrease the described Na gain [2,3]. Despite the clear understanding of
the importance of these effects, the interaction of NO and
8-iso-PGF2α in the cTAL has not been evaluated to elucidate their outcomes.
Na+ regulation has been previously reported at several
nephron segments mediated by agents such as NO and
angiotensin II in the cTAL [4,5], NO and arginine vasopressin at the cortical collecting duct level [6], and other segments [7]. The final effect of the interaction between NO
and 8-iso-PGF2α is based on the intracellular activation
of different regulators. Actually, whereas NO inhibits NaCl
reabsorption by increasing intracellular cyclic guanosine
monophosphate (cGMP) and decreasing cyclic adenosine
monophosphate (cAMP) levels [7], 8-iso-PGF2α increases cAMP. The final effect will be elicited when one cyclic
nucleotide preponderantly represses the other. When attempting to understand the crosstalk regulation of cyclic
nucleotide concentrations, one must consider that such
regulation can occur at the level of cyclic nucleotide synthesis, phosphodiesterase-mediated degradation, or even
cellular efflux. Thus, we hypothesized that, in cTAL, persistent effects of 8-iso-PGF2α on Na reabsorption prevail
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over the shorter-acting NO effects, and protein kinase A
(PKA) activation is required for such interaction.

Methods
Animals
Male New Zealand white rabbits (700–1,200 g) were
housed for 3 to 7 days before the study for acclimatization. The experiments were approved by the Institutional
Animal Care and Use Committee of the J. Robert Cade
Foundation (No. FJRC #2009) in Córdoba, Argentina. All
animals were housed and handled according to the Public
Health Service Policy on Humane Care and Use of Laboratory Animals.
Preparation and dissection of the cortical thick ascending
limb of Henle
Animals were anesthetized with sodium thiopental (30
mg/kg, intravenously) and xylazine (20 mg/kg, intramuscularly) plus ketamine (50 mg/kg, intramuscularly). The
kidney was exposed and bathed in ice-cold saline and then
excised and cut into coronal slices along the longitudinal
axis. The slices were placed in oxygenated physiological saline in a temperature-regulated chamber at 4°C. The cTAL
of Henle was dissected from the medullary ray under a stereomicroscope as previously described [6,8].
Perfusion of thick ascending limbs
cTALs in a temperature-regulated chamber were perfused
between concentric glass pipettes at 37°C as described [6].
The basolateral bath was exchanged at a rate of 0.5 mL/
min. A total of five to eight tubules were analyzed during
each protocol. Time-control experiments were conducted
to ensure the stability of tubular transport. Chloride absorption (JCl) was measured as previously described [6,9].
cTALs were perfused and equilibrated for 20 minutes, and
basal Cl absorption was calculated two to three times. Tested compounds, including 8-iso-PGF2α, were either added
to or removed from the lumen or bath as indicated. After
a 20-minute equilibration period, tubular fluid was again
collected 2 or 3 times.
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Chloride concentrations in the perfusate and collected
fluid
Chloride concentrations were measured by microfluorometry [10]. Because water is not reabsorbed by the thick
ascending limb, JCl was calculated by the following equation: JCl = CR × (C0Cl – C1Cl), where CR = collection rate normalized/tubule length, C0Cl = chloride concentration in the
perfusion solution, and C1Cl = chloride concentration in the
collected fluid.
Cyclic adenosine monophosphate
cAMP was measured as previously described [1]. Briefly,
tubules were isolated and incubated in 95 µL perfusion
solution containing 1-mM 3-isobutyl-1-methylxanthine
at 37°C for 10 minutes before adding 5-µL medium containing inhibitors or hormones. The reaction was stopped
30 minutes later with methanol (100 µL), and cAMP and
cGMP levels were measured by an enzyme immunoassay
(EIA; Cayman Chemical, Ann Arbor, MI, USA). The samples were centrifuged, the supernatant was transferred to
another tube and dried in a Savant centrifugal vacuum
concentrator, and the pellet was reconstituted in 110-µL
sodium acetate buffer. The cAMP standard was treated the
same way. The results were expressed as fmol/min/mm
tubule length.

bath, JCl was 333 ± 35 pmol/min/mm. SNP (1 mM) in the
bath reduced JCl to 195 ± 26 pmol/min/mm (p = 0.01 vs.
basal; n = 5) (Fig. 1), a 41% decrease, and remained inhibited for the rest of the experiment (196 ± 22 pmol/min/mm).
In vivo, this reduction in JCl should increase diuresis. In
time-control experiments, JCl remained constant throughout the experimental period.
Next, we tested whether 8-iso-PGF2α stimulates JCl in
the presence of SNP. Basal JCl was 330 ± 18 pmol/min/mm;
when SNP (1 mM) was added to the bath, JCl decreased to
191 ± 19 pmol/min/mm. After adding 8-iso-PGF2α (100
μM) to the lumen, JCl increased to 346 ± 39 pmol/min/mm
(p < 0.02 vs. NO; n = 5) (Fig. 2). We tested this concentration
since those lower did not affect JCl [1]. Next, we evaluated
the effect of 8-iso-PGF2α present in the basolateral side.
Basal JCl was 235 ± 38 pmol/min/mm, which decreased in
the presence of SNP (1 mM) to 139.4 ± 27 pmol/min/mm
and increased to 297 ± 29 pmol/min/mm in the presence
of 8-iso-PGF2α (100 μM; p < 0.02 vs. NO; n = 5) (Fig. 3).
These data indicate that the maximal NO effect on cTAL is
insufficient to prevent the 8-iso-PGF2α-stimulated NaCl
reabsorption.
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Statistics
Data were analyzed by paired and unpaired Student t tests
and one-way analysis of variance, and results with p < 0.05
were significant. Results were expressed as mean ± standard error of the mean.
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Results
Since the 8-iso-PGF2α/NO interaction in cTAL is uncertain, we chose a maximum NO bioavailability model. As
described, the micro-isolated rabbit cTALs were transferred to a temperature-regulated chamber and perfused
between concentric glass pipettes at 37°C [6] with the NO
donor sodium nitroprusside (SNP) in a concentration that
decreases transport by 40% as endogenous NO is inhibited
in this nephron segment [11]. Before adding SNP to the
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Figure 1. SNP inhibits JCl; nitric oxide decreases JCl in the cTAL.
Basal JCl was 333.5 ± 35.2 pmol/min/mm and the addition of SNP
(1 mM) decreased it to 195.9 ± 26.1 pmol/min/mm (*p = 0.01
vs. basal; n = 5, one-way analysis of variance [Holm-Sidak test])
and remained decreased during the experimental time (196.5 ±
22.3 pmol/min/mm).
cTAL, cortical thick ascending limb; JCl, chloride absorption; SNP,
sodium nitroprusside.
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Figure 3. SNP-induced inhibition of JCl was prevented by 8-isoPGF2α on the basolateral side.
*p < 0.03 vs. control period; n = 4, one-way analysis of variance
(Holm-Sidak test).
JCl, chloride absorption; SNP, sodium nitroprusside; 8-iso-PGF2α,
8-iso-prostaglandin-F2α.

In cTAL, 8-iso-PGF2α stimulates JCl via a cAMP-dependent mechanism [1], while NO inhibits chloride reabsorption by stimulation of a cGMP-stimulated phosphodiesterase, which decreases cAMP level [12]. Thus, we evaluated
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Figure 2. SNP-induced inhibition of JCl was prevented by
8-iso-PGF2α on the luminal side.
*p < 0.003 vs. basal; n = 5, one-way analysis of variance (Holm-Sidak test).
JCl, chloride absorption; SNP, sodium nitroprusside; 8-iso-PGF2α,
8-iso-prostaglandin-F2α.
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Figure 4. Effect of 100 μM 8-isoPGF2α on the presence of SNP,
a NO donor. Basal cAMP was 56.3 ± 13.1 fmol/min/mm, in the
presence of the NO donor, 57.8 ± 6.1 fmol/min/mm, and 8-iso-PGF2α increased it to 92.1 ± 2.9 fmol/min/mm (*p < 0.001 vs. control and vs. SNP period; n = 10, one-way analysis of variance [Tukey
honestly significant difference post hoc test]).
cAMP, cyclic adenosine monophosphate; JCl, chloride absorption; NO, nitric oxide; SNP, sodium nitroprusside; 8-iso-PGF2α,
8-iso-prostaglandin-F2α.

the effect of 8-iso-PGF2α on cAMP in the presence of a NO
donor, SNP (1 mM). Basal cAMP was 56.3 ± 13.1 fmol/min/
mm, while that in the presence of the NO donor was 57.8
± 6.1 fmol/min/mm, the addition of 8-iso-PGF2α to which
increased cAMP to 92.1 ± 2.9 fmol/min/mm (n = 10, p <
0.04) (Fig. 4). Thus, 8-iso-PGF2α-stimulated NO-inhibited
JCl is associated with a 60% increase in cAMP.
In the cTAL, PKA mediates the effect of 8-iso-PGF2α
on JCl. Thus, we evaluated the effect of 8-iso-PGF2α on
SNP-inhibited JCl in the presence of H89 (10 mM), a PKA
inhibitor. Basal JCl was 249 ± 13 pmol/min/mm and decreased to 173 ± 14 pmol/min/mm when SNP (1 mM)
was added to the bath. Addition of H89 to the bath did not
change JCl significantly (158 ± 10 pmol/min/mm). Under
these conditions, 8-iso-PGF2α could not stimulate SNP-inhibited JCl (147 ± 15 pmol/min/mm) (Fig. 5). Time control
did not change during the experiment (280 ± 22 pmol/
min/mm vs. 282 ± 36 pmol/min/mm). These data indicate that 8-iso-PGF2α requires PKA activity to reverse the
NO-inhibited JCl.
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Figure 5. Effect of 8-iso-PGF2α on NO-induced JCl inhibition in
the presence of H89, a PKA inhibitor.
*p < 0.03 vs. control period; n = 5, one-way analysis of variance
(Holm-Sidak test).
JCl, chloride absorption; NO, nitric oxide; PKA, protein kinase A;
8-iso-PGF2α, 8-iso-prostaglandin-F2α.

Discussion
To our knowledge, this is the first report showing that
8-iso-PGF2α can override NO’s diuretic effects in the cTAL,
suggesting that Na+ retention will prevail over Na+ excretion
in clinical conditions associated with increased 8-iso-PGF2α level. Although in the kidney, discrete 8-iso-PGF2α and
NO effects have both been shown in vivo and in vitro, we
designed this in vitro investigation to identify the local interaction and final effect of these two autacoids on chloride
transport at the nephron segment.
Despite the well-known importance of prostaglandin
in Na reabsorption, the effects of its derivatives are less
clear. We evaluated the effects of 8-iso-PGF2α binding to
the G-protein coupled receptor thromboxane A2 (TXA2)
receptor, localized in the thick ascending limb segment
[13,14]. This 8-iso-PGF2α is a modified prostaglandin produced by nonenzymatic oxidation of prostaglandin-F2α by
reactive oxygen species [15,16] and induces vasoconstriction in the kidney and can impact renal blood flow [17].
Our data demonstrate that the NO donor decreases chloride reabsorption in the thick ascending limb of Henle; under these circumstances, 8-iso-PGF2α is activated by PKA
and stimulates Cl– reabsorption. In vivo, this interaction
results in a decrease of natriuresis and sodium increase.

The significance of this interaction resides not only in improving understanding of the normal physiology, but also
in the prevention and treatment of many conditions such
as hypertension, chronic renal failure, and cirrhosis, where
isoprostanes increase and an Na retention state prevails
[18].
The compound 8-iso-PGF2α binds the TXA2 receptor, a
peroxidized derivative of prostaglandin-F2 localized in the
basolateral and apical membrane of the thick ascending
limb segment, which then activates cAMP production [14].
Following the release of 8-iso-PGF2α, sudden activation
of the TXA2 receptor receptor in the thick ascending limb
occurs [1], stimulating chloride reabsorption via cAMP.
Simultaneously, NO inhibits 8-iso-PGF2α via cGMP generation. Therefore, the interaction between these two intracellular mechanisms could regulate sodium transport.
In the kidney, 8-iso-PGF2α induces vasoconstriction,
which can modulate renal blood flow [19]. In the thick ascending limb, TXA2 receptor release stimulates PKA and
induces an increase in chloride reabsorption across the
Na-K-Cl cotransporter 2 (NKCC2) [20]. Increased concentrations of 8-iso-PGF2α and other isoprostanes have been
observed in both the urine and plasma of hypertensive
subjects. The enhanced NaCl retention in response to
8-iso-PGF2α might contribute to the pathogenesis of hypertension [20]. In the distal nephron, NO decreases cAMP,
which reduces fluid absorption via PKA [21].
We further investigated whether 8-iso-PGF2α could reverse NO effects when PKA is inhibited. This experiment
should establish whether the interaction between the
mechanisms linking 8-iso-PGF2α and NO precedes or follows activation of PKA. In the presence of PKA inhibition,
8-iso-PGF2α did not change JCl, indicating that PKA activity
is required to reverse the NO-inhibited JCl. Moreover, these
results indicate that 8-iso-PGF2α reverses NO-induced inhibition of JCl via a mechanism involving activation of PKA.
Since PKA is mainly activated by cAMP, we studied cAMP
and found that NO was not able to reduce the cAMP level
induced by 8-iso-PGF2α.
Nevertheless, the effects of 8-iso-PGF2α and NO on NaCl
excretion have been shown in several models [22]. The
decreased urinary Na+ excretion caused by systemic nitric
oxide synthase (NOS) inhibition correlates with higher urinary 8-iso-PGF2α [23,24]. Also, the superoxide scavenger
Tempol blunts these changes, suggesting that inhibition of
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NO synthesis enhances endogenous superoxides, which
could increase renal 8-iso-PGF2α level. These studies,
however, show correlation but no direct interaction in the
transport mechanisms. At any rate, 8-iso-PGF2α increases
Cl– by stimulating cAMP synthesis [1].
In contrast, the effect by which NO inhibits NKCC2 activity might involve both an increase in cGMP [12,25,26] and a
decrease in cAMP [27]. In our study, the NO donor did not
decrease cAMP, whereas cGMP can play an essential role in
the NO-inhibited JCl. This effect might involve protein trafficking, limiting the total pool of NKCC2 at the membrane
level [28] since 8-iso-PGF2α’s increase of JCl is mediated by
NKCC2 [1].
The mechanism(s) by which cGMP acts to regulate
trafficking of the transporter might involve a decrease in
insertion of the transporter into the membrane. Although
evidence exists supporting the constitutive degradation of
surface NKCC2, which is hypothesized to occur by decreasing NKCC2 level due to increasing NKCC2 ubiquitination
and proteasomal degradation [28], it appears plausible that
NO acts by increasing cGMP, which decreases cAMP [27]
to lead to a reduction in exocytic insertion of NKCC2 into
the apical membrane, reducing the number of transporters [19]. This process results in lower NKCC2 activity and
blunted net NaCl reabsorption.
Our experiments demonstrate that interaction with
8-iso-PGF2α increases intracellular cAMP; in the presence
of H89, 8-iso-PGF2α does not increase chloride reabsorption. These results show that the interaction occurs after
activation of PKA since H89 prevented 8-iso-PGF2α and JCl
inhibited NO and not because 8-iso-PGF2α blunts cGMP
formation. Indeed, we found that NO caused no significant
change in 8-iso-PGF2α-stimulated cAMP level. This indicates
that NO-stimulated phosphodiesterase activity has little or
no effect on 8-iso-PGF2α-stimulated cAMP level. This notion might not apply to other cellular compartments, where
NO-stimulated phosphodiesterase could be activated separately from 8-iso-PGF2α-stimulated cAMP. Thus, 8-iso-PGF2α might interact with NO at the level of cAMP or cGMP.
The pathomechanism whereby 8-iso-PGF2α prevents
NO-inhibited JCl might be observed under several conditions characterized by increased blood pressure, such as
hypertension and chronic renal failure. In such conditions,
urinary 8-iso-PGF2α 9 [29] and cAMP [30] are elevated as
well as other oxidative stress mediators. On the contrary,
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NO production is impaired in part due to limitations on
substrate (L-arginine) availability and increased circulating
levels of endogenous NO synthase inhibitors, in particular
asymmetric dimethylarginine and reduced renal cortex
abundance of the neuronal NOS [31]. This effect of NO
correlates with urinary cGMP level [32]. This pathological
condition is characterized by sodium retention as a consequence of enhanced sympathetic activity [33] and increase synthesis of intrarenal angiotensin II synthesis [34],
endothelin-1 [35], and 8-iso-PGF2α, all of which stimulate
sodium reabsorption. In contrast, the antinatriuretic effect
of NO is blunted under these conditions, leading to sodium
retention, hypertension, fibrosis, and end-organ damage.
The beneficial effect of 8-iso-PGF2α blockade has been
observed in several animal models. Studies in diabetic
animals with nephropathy showed that supplementation
with vitamin E via reduced production of transforming
growth factor-beta reduced urinary isoprostane level and
improved proteinuria and blood urea nitrogen level [36]. In
spontaneously animal models of hypertension and angiotensin II-induced hypertension, both with elevated plasma
isoprostane level, Tempol administration decreases renal
isoprostane excretion and lowers blood pressure [4,37].
These beneficial effects observed by isoprostane blockade (and increase in NO availability) can prevent sodium
overload, hypertension, chronic fibrosis, and end-organ damage. Clinical evaluations are under review to
estimate the beneficial effect of isoprostane blockade
(NCT03358524, NCT01125501, and NCT00552227).
Although the results of this report can explain important
pathophysiological conditions, it has some limitations. One
important limitation is the H89, despite being the most
commonly used PKA inhibitor, might have nonspecific inhibitory effects.
In conclusion, 8-iso-PGF2α can increase JCl at the kidney
cTAL via stimulation of PKA even when JCl is inhibited by
NO. This increase of JCl is associated with a higher cAMP
tissue concentration, which cannot be inhibited by NO,
indicating the importance of 8-iso-PGF2α as a therapeutic
intervention in kidney repair and functional restoration to
regulate fluid and electrolyte balance.
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